



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/486,971	05/19/2000	VELI-MATTI LEHTOLA	933-154PCT	7050

2292 7590 04/16/2002

BIRCH STEWART KOLASCH & BIRCH
PO BOX 747
FALLS CHURCH, VA 22040-0747

EXAMINER

BENNETT, RACHEL M

ART UNIT	PAPER NUMBER
----------	--------------

1615

DATE MAILED: 04/16/2002

20

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/486,971

Applicant(s)

LEHTOLA ET AL.

Examiner

Rachel M. Bennett

Art Unit

1615

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 22 March 2002.
- 2a) ☒ This action is FINAL. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1,3,4,6,11 and 14-19 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1,3,4,6,11 and 14-19 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☒ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____.
- 4) ☐ Interview Summary (PTO-413) Paper No(s). _____.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: _____.

Art Unit: 1615

DETAILED ACTION

The examiner acknowledges receipt of Amendment D and Declaration filed 3/22/02.

Claims 1, 3-4, 6, 11, 14-19 are pending.

Specification

Claim Rejections - 35 USC § 103

1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

2. Claims 1, 3-4, 6, 11, 14-19 are rejected under 35 U.S.C. 103(a) as being unpatentable over Posti et al. (US 5525354) in further view of Sherwood (WO 96/21429) and Remington's Pharmaceutical Sciences.

Posti discloses a pharmaceutical preparation for oral use containing a pharmacologically acceptable salt of a dichloromethylene bisphosphonic acid, a clodronate, especially disodium clodronate (see abstract, column 1 lines 6-10). The preparation may also contain additives, such as carriers, diluents, fillers, lubricants, and disintegrating agents, which are all known in the art (see column 2 lines 18-22). More specifically, microcrystalline cellulose as a filler and colloidal silicon dioxide may be used as a lubricant (see column 2 lines 41-51). The preparation is carried out using known tableting, granulating or pelletization techniques (see column 2 lines 52-54). Example 1 illustrates a tablet comprising disodium clodronate, microcrystalline cellulose and silicon dioxide. The desired amount of clodronate can vary within wide limits from 10 to 95% by weight (see column 2 lines 22-25). The preparation also comprises of microcrystalline

Art Unit: 1615

cellulose and silicon dioxide comprises about 8 to 20% by weight, and lubricants and/or disintegrants comprise about 0.5 to 10% by weight (see example 1). Posti does not disclose preparing the microcrystalline cellulose and silicon dioxide in a particulate agglomerate of co-processed microcrystalline cellulose and silicon dioxide.

Sherwood discloses a microcrystalline cellulose-based excipient having improved compressibility, whether utilized in direct compression, dry granulation, or wet granulation formulations. The excipient is an agglomerate of microcrystalline cellulose particles and from about 0.1% to about 20% silicon dioxide particles, by weight of the microcrystalline silicon dioxide particles, by weight of the microcrystalline cellulose, wherein the microcrystalline cellulose and silicon dioxide are in intimate association with each other (see abstract). Sherwood discloses known methods of tableting. Lubricants are typically added to avoid the material(s) being tabletted from sticking. In addition to lubricants, solid dosage forms often contain diluents. Diluents are frequently added in order to increase the bulk weight of the material to be tabletted in order to make the tablet a practical size for compression. Disintegrants are often included in order to ensure the ultimately prepared compressed solid dosage form has an acceptable disintegrating rate in an environment of use. Typically excipients are added to the formulation, which impart good flow and compression characteristics to the material as a whole. Compared to other directly compressible excipients, microcrystalline cellulose is generally considered to exhibit superior compressibility and disintegration properties (see pages 2 and 4). Sherwood's excipient comprises a particulate agglomerate of copressed microcrystalline cellulose and from about 0.1% to about 20% silicon dioxide, by weight of the microcrystalline cellulose, the microcrystalline cellulose and silicon dioxide being in intimate association with each other (see

Art Unit: 1615

page 9). Advantages of the disclosed excipient include excellent disintegration properties and improved compressibility (see page 11). By "intimate association", it is meant that the silicon dioxide has in some manner been integrated with the microcrystalline cellulose particles e.g., via a partial coating of the microcrystalline cellulose particles, as opposed to a chemical interaction of the two ingredients. It is most preferred the microcrystalline cellulose and silicon dioxide are coprocessed, resulting in an intimate association of these ingredients, rather than being combined as a dry mixture. After a uniform mixture of the ingredients is obtained in a suspension, the suspension is dried to provide a plurality of microcrystalline cellulose-based excipient particles having enhanced compressibility. It is preferred that the suspension be dried using spray-drying techniques, as they are known in the art (see page 21).

Remington discloses microcrystalline cellulose as a tablet diluent and disintegrant and silicon dioxide as a tablet diluent and as a suspending and thickening agent in pharmaceutical preparations (see pages 1319 and 1325).

It is the position of the examiner, that it would have been obvious to one of ordinary skill in the art at the time the invention was made to have modified the composition of Posti by substituting the microcrystalline cellulose-excipient taught by Sherwood for the microcrystalline cellulose and silicon dioxide of Posti because of the expectation of achieving excellent disintegration properties and improved compressibility as taught by Sherwood. Remington discloses microcrystalline cellulose and silicon dioxide are known in the art as excipients for tableting, while Sherwood discloses the combination of the two has improved characteristics. Therefore, substituting one excipient, as taught by Sherwood, for two excipients as taught by Posti, would not only have the advantages taught by Sherwood, but would also add convenience

Art Unit: 1615

to the overall process of making. The expected result would a tablet comprising dichloromethylene biphosphonic acid and microcrystalline cellulose-based excipient.

Response to Arguments

3. Applicant's arguments with respect to claims 1, 3-4, 6, 11 have been considered but are moot in view of the new ground(s) of rejection.

4. The Declaration under 37 CFR 1.132 filed 3/22/02 is insufficient to overcome the rejection of claims 1, 3-4, 6, 11 based upon the new grounds of rejection.

Conclusion

5. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the date of this final action.

Art Unit: 1615

Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Rachel M. Bennett whose telephone number is (703) 308-8779.

The examiner can normally be reached on Monday through Friday, 8:00 A.M. to 4:30 P.M..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman K. Page can be reached on (703) 308-2927. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 305-3592 for regular communications and (703) 309-7924 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1234.

R. Bennett:RMB
April 9, 2002

THURMAN K. PAGE
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600